Shortage declared over

The US FDA has formally determined that the shortages of semaglutide injection products (Ozempic, Wegovy) and tirzepatide injection products (Mounjaro, Zepbound) have been resolved. Both drugs were added to the FDA's Drug Shortage List during the explosive demand surge of 2022–2024, which was driven by the popularity of GLP-1 receptor agonists for weight management.

With the shortage formally resolved, the FDA has clarified that compounding pharmacies — which were permitted to produce compounded copies of these drugs under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act while they were in shortage — must now cease production. The FDA has provided transition periods for winding down distribution of existing compounded stock.

Why this matters for research peptides

The GLP-1 shortage created a grey market ecosystem. As pharmaceutical-grade semaglutide and tirzepatide became scarce, many individuals turned to compounded versions from pharmacies, and some turned to research-grade peptides sold online. Research peptide vendors — including UK-based suppliers — saw increased demand for semaglutide, tirzepatide, retatrutide, and related peptides marketed for research purposes.

The resolution of the shortage could reduce demand pressure on the research peptide market. However, the high cost of branded GLP-1 medicines means that research-grade alternatives may remain attractive to some buyers, even as the legal and regulatory landscape tightens.

UK regulatory context

In the UK, the MHRA regulates the manufacture and supply of medicines. GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are prescription-only medicines (POMs). Supplying these active substances without appropriate pharmaceutical licensing is illegal in the UK.

Research peptides are sold legally for research purposes only — not for human consumption. The MHRA has previously taken enforcement action against vendors who market research peptides for human use or who supply unlicensed medicines under the guise of research products. The FDA's compounding crackdown in the US may signal increased regulatory scrutiny of the GLP-1 peptide supply chain globally.

Researchers purchasing GLP-1 receptor agonist peptides in the UK should be aware that:

  • These substances are POMs when intended for human use
  • Research-grade peptides are sold for laboratory research only and must not be consumed
  • Vendors must clearly label products as 'not for human consumption' and 'for research use only'
  • The MHRA continues to monitor the UK market for illegal supply of GLP-1 medicines

Supply chain implications

The end of the US shortage reflects increased manufacturing capacity by Novo Nordisk (semaglutide) and Eli Lilly (tirzepatide). Both companies have invested heavily in expanding production. This improved supply is gradually reaching international markets, including the UK, where GLP-1 medicine availability has improved through 2024–2025.

For the research peptide market, improved pharmaceutical supply could mean:

  • Reduced pressure on research-grade GLP-1 peptide vendors
  • Potential price stabilisation or reduction for research-grade semaglutide and tirzepatide
  • Increased regulatory clarity as the grey market contracts
  • Continued strong demand for emerging GLP-1 peptides (retatrutide, orforglipron, survodutide) that are not yet commercially available

What researchers should do

UK-based researchers working with GLP-1 receptor agonist peptides should:

  1. Verify vendor legitimacy — ensure suppliers are selling for genuine research purposes with appropriate labelling
  2. Check COAs — request and review Certificates of Analysis for purity verification
  3. Follow UK law — understand that GLP-1 receptor agonists are POMs when intended for human use
  4. Monitor regulatory developments — the MHRA may issue updated guidance as the global supply situation evolves

Bottom line

The FDA's resolution of the GLP-1 shortage and its crackdown on compounding marks a significant regulatory shift. While primarily a US action, it affects the global peptide research ecosystem. UK researchers should ensure they are sourcing peptides legally for research purposes and stay informed of MHRA guidance as the landscape continues to evolve.

This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.